Re-inventing tumor targeting
Thermosome is a drug development company focused on targeted tumor therapy combined with immune stimulation for improved cancer therapy. At its core is a new tumor targeting concept, which allows for increased local drug concentrations to achieve improved clinical treatment efficacy.
Latest news
Thermosome announces the appointment of Dr. Sabine Hauck as Chief Technology Officer (CTO)
Thermosome Announces Further Dose Escalation in Phase I Trial with Lead Program THE001
Thermosome Appoints Dr. Frank Hermann, MD, as Chief Medical Officer and Adds Prof. Alessandro Gronchi, MD, to Clinical Advisory Board
Upcoming events
ESMO Congress
September 13–17, 2024
Barcelona, Spain
Sachs Biotech in Europe Forum
September 25–26, 2024
Basel, Switzerland
